AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 88_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 25_CD Disposal_NN of_IN business_NN operations_NNS 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS 70_CD Current_JJ assets_NNS 34_CD Creditors_NNS due_JJ within_IN one_CD year_NN 17_CD Book_NN value_NN of_IN net_JJ assets_NNS disposed_VBD 87_CD Less_RBR :_: Cash_NN included_VBD in_IN undertakings_NNS disposed_VBD 7_CD Cash_NN consideration_NN 80_CD The_DT sale_NN consideration_NN received_VBN is_VBZ in_IN relation_NN to_TO the_DT sale_NN of_IN Marlow_NNP Foods_NNP Limited_NNP ,_, which_WDT was_VBD completed_VBN on_IN 23_CD May_NNP 2003_CD ._.
Marlow_NNP Foods_NNP Limited_NNP results_NNS have_VBP been_VBN consolidated_VBN for_IN the_DT period_NN up_IN to_TO disposal_NN ._.
Prior_RB to_TO its_PRP$ disposal_NN ,_, Marlow_NNP Foods_NNP Limited_NNP contributed_VBD $_$ 6m_CD to_TO operating_VBG cash_NN flows_NNS and_CC absorbed_VBN $_$ 1m_CD in_IN respect_NN of_IN fixed_JJ capital_NN expenditure_NN ._.
There_EX was_VBD no_DT gain_NN or_CC loss_NN on_IN disposal_NN ._.
26_CD Reconciliation_NNP of_IN net_JJ cash_NN flow_NN to_TO movement_NN in_IN net_JJ funds_NNS 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Decrease_NN in_IN cash_NN 4_CD 22_CD 396_CD Cash_NN outflow_NN inflow_NN from_IN decrease_NN increase_NN in_IN loans_NNS and_CC short_JJ term_NN borrowings_NNS 345_CD 118_CD 35_CD Cash_NN outflow_NN inflow_NN from_IN increase_NN decrease_NN in_IN short_JJ term_NN investments_NNS 771 806 260_CD Change_NNP in_IN net_JJ funds_NNS resulting_VBG from_IN cash_NN flows_NNS 430 902 691_CD Exchange_NNP movements_NNS 82_CD 75_CD 47_CD Movement_NNP in_IN net_JJ funds_NNS 348 977 738_CD Net_JJ funds_NNS at_IN 1_CD January_NNP 3,844_CD 2,867_CD 3,605_CD Net_JJ funds_NNS at_IN 31_CD December_NNP 3,496_CD 3,844_CD 2,867_CD
